Tirzepatide vs Bariatric Surgery
Tirzepatide produces 18–22% mean weight loss — narrower than the historical gap between GLP-1 monotherapy and bariatric surgery. Surgery remains more durable, but tirzepatide is now a credible non-surgical alternative for many candidates.
Tirzepatide is the provider-reviewed first-line for most candidates and avoids surgical risk.
Bariatric surgery is appropriate when BMI thresholds and comorbidity warrant surgical intervention and the candidate accepts permanence.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Does tirzepatide rival surgery?
It narrows the gap meaningfully but does not match surgical magnitude in head-to-head trials.
Can tirzepatide be used post-op?
Yes — provider-reviewed adjunctive use is common for incomplete response or regain.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment